contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


neola-medicals-ceo-shares-clinical-progress-and-recent-milestones-in-summer-2025-investor-letter

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Neola Medical operates in the medical technology sector. The company focuses on neonatal care, where it develops medical equipment. Examples of products that the company provides to the healthcare sector include technical monitoring and follow-up of lung capacity in premature infants. In addition to the main product, ancillary products and disposables are offered. The largest operations are found in the Nordic market. Neola Medical was founded in 2016 and is headquartered in Sweden.

Neola Medical

As summer unfolds, Neola Medical highlights important progress in its clinical development program. The company has successfully enrolled the first baby in the ongoing clinical pilot study on...

<div class="mfn-preamble"><p><strong>As summer unfolds, Neola Medical highlights important progress in its clinical development program. The company has successfully enrolled the first baby in the ongoing clinical pilot study on preterm born babies in Sweden, marking the first real-world use of Neola® to monitor the lungs of a baby in neonatal intensive care. In parallel, preparations advance for the pivotal clinical study in the U.S., following IRB approval and a signed agreement with a prominent neonatal intensive care unit (NICU) at Children’s Regional Hospital at Cooper, Camden, New Jersey, USA. This agreement with one of Neola Medical’s strategically important study sites enables the initiation of the pivotal clinical study on preterm born babies with its medical device for continuous lung monitoring, Neola®, which will play a central role in building the clinical evidence base required to support the planned FDA application for market authorization.</strong></p></div><div class="mfn-body"><p>“The first real-world use of Neola® to monitor the lungs of a baby, in our ongoing clinical pilot study in Sweden, marks a historic milestone for the company. At the same time, we are making important progress in preparing our pivotal clinical study in the U.S., which will support the foundation of our planned FDA application for market authorization,” says CEO Hanna Sjöström.</p><p>Read more in the investor letter summer 2025, attached to this press release and available on the company’s website <a rel="noopener" href="http://www.neolamedical.com/">www.neolamedical.com</a></p></div><div class="mfn-footer mfn-contacts mfn-39c2feb1dc3d"><p><strong class="mfn-heading-1">For further information, contact:</strong><br>Hanna Sjöström, CEO<br>e-mail: <a rel="noopener" href="mailto:hanna.sjostrom@neolamedical.com">hanna.sjostrom@neolamedical.com</a></p></div><div class="mfn-footer mfn-about mfn-112561f0eca8"><p><strong class="mfn-heading-1">About Neola Medical</strong><br>Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden’s longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/c9ff9775-955b-4773-99ab-c8678861fe26/neola-medicals-ceo-shares-clinical-progress-and-recent-milestones-in-summer-2025-investor-letter.pdf" class="mfn-generated mfn-primary">Neola Medical’s CEO shares clinical progress and recent milestones in summer 2025 investor letter</a><br><a rel="noopener" href="https://storage.mfn.se/c0321fcd-28c8-4fdd-b4e7-3758419f86ae/neola-medical-investor-letter-summer-2025.pdf">Neola Medical Investor Letter Summer 2025</a></p></div>

Neola Medical’s CEO shares clinical progress and recent milestones in summer 2025 investor letter